Mineralys Therapeutics (MLYS) Accounts Payables (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 199.2% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 199.2% YoY), and the FY2025 full-year result was $2.0 million, up 321.09% from the prior year.
• Accounts Payables fell to $1.1 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.6 million in Q3 2023 to a low of $373000.0 in Q1 2025.
• A 5-year average of $2.1 million and a median of $2.0 million in 2022 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 321.09% in 2025, while the deepest fall reached 91.25% in 2025.
• Tracing MLYS's Accounts Payables over 5 years: stood at $1.9 million in 2022, then slumped by 68.48% to $601000.0 in 2023, then dropped by 20.3% to $479000.0 in 2024, then soared by 321.09% to $2.0 million in 2025, then sank by 44.67% to $1.1 million in 2026.
• Business Quant data shows MLYS's Accounts Payables at $1.1 million in Q1 2026, $2.0 million in Q4 2025, and $1.1 million in Q3 2025.